Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by Nwam LLC

Nwam LLC boosted its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 0.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 913,051 shares of the biotechnology company’s stock after buying an additional 2,575 shares during the quarter. Nwam LLC owned 1.08% of Anavex Life Sciences worth $9,806,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Anavex Life Sciences by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after buying an additional 51,946 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Anavex Life Sciences by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 14,892 shares in the last quarter. Barclays PLC raised its stake in shares of Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after purchasing an additional 64,101 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Anavex Life Sciences by 2.9% in the 4th quarter. Rhumbline Advisers now owns 123,699 shares of the biotechnology company’s stock valued at $1,329,000 after purchasing an additional 3,498 shares in the last quarter. Finally, Carnegie Investment Counsel raised its stake in shares of Anavex Life Sciences by 4.7% in the 4th quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock valued at $825,000 after purchasing an additional 3,445 shares in the last quarter. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Stock Up 1.0 %

AVXL opened at $8.07 on Thursday. The firm has a market cap of $686.43 million, a price-to-earnings ratio of -14.67 and a beta of 0.69. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The company’s 50-day moving average price is $9.92 and its 200 day moving average price is $7.83.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. Research analysts anticipate that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on AVXL shares. D. Boral Capital restated a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, February 18th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.